PRevention Of lymphoedema by Therapeutic Elastic Compression hoses: Treatment efficacy

| Submission date | Recruitment status | Prospectively registered |
|-------------------|----------------------|---|
| 02/05/2007 | No longer recruiting | Protocol |
| Registration date | Overall study status | Statistical analysis plan |
| 02/05/2007 | Completed | Results |
| Last Edited | Condition category | Individual participant data |
| 23/09/2021 | Surgery | Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr M.M. Stuiver

Contact details

The Netherlands Cancer Institute
Antoni van Leeuwenhoek Hospital
Department of Physiotherapy
Amsterdam
Netherlands
1066 CX
+31 (0)20 512 2586
m.stuiver@nki.nl

Additional identifiers

Protocol serial number

NL917 (NTR941)

Study information

Scientific Title

PRevention Of lymphoedema by Therapeutic Elastic Compression hoses: Treatment efficacy

Acronym

PROTECT

Study objectives

H0: incidence of lymphoedema in hose-group equals non-hose group.

H1: incidence of lymphoedema in hose group does not equal non-hose group.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the Medical Ethical Comittee of The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital on the 4th September 2006 (ref: PTC06.1170/MO6PRO).

Study design

Randomised, active controlled, parallel group, multicentre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Compression hoses, lymphoedema, inguinal lymph node dissection

Interventions

Therapeutic elastic compression hose for a period of six months, in addition to standard regimen of early ambulation and patient education.

Intervention Type

Procedure/Surgery

Phase

Not Specified

Primary outcome(s)

Incidence of lymphoedema (survival without lymphoedema); surface measurements are used to calculate limb volume to establish the diagnosis of lymphoedema at T0, T1, T2, T3, T4 and T5.

Key secondary outcome(s))

- 1. Early surgical complications (wound breakdown, lymphocele formation, wound infection), measured at T2
- 2. Genital oedema, measured at T0, T1, T2, T3, T4 and T5
- 3. Health related quality of life, measured at T0, T4 and T5
- 4. Body image, measured at T4 and T5
- 5. Compliance to usage of the hose, measured at T2, T3 and T4
- 6. Use of professional homecare
- 7. Lymphoedema requiring treatment

T0: day of admittance

T1: day of dismissal

T2: first outpatient visit two months after dismissal

T3: second outpatient visit four months after dismissal

T4: third outpatient visit six months after dismissal

T5: fourth outpatient visit 12 months after dismissal

Completion date

31/12/2007

Eligibility

Key inclusion criteria

- 1. 18 years or older
- 2. Inguinal lymph node dissection because of metastases of melanoma or urogenital tumour

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

- 1. Deep venous thrombosis
- 2. Manifest lymphoedema or episodes of lymphoedema in the past
- 3. Isolated limb perfusion treatment
- 4. Oedema as a result of venous insufficiency
- 5. Psychiatric disorders
- 6. Lacking basic proficiency in Dutch
- 7. Skin diseases of the leg

Date of first enrolment

01/10/2006

Date of final enrolment

31/12/2007

Locations

Countries of recruitment

Study participating centre
The Netherlands Cancer Institute
Amsterdam
Netherlands
1066 CX

Sponsor information

Organisation

Netherlands Cancer Institute (NKI) (The Netherlands)

ROR

https://ror.org/03xqtf034

Funder(s)

Funder type

Research organisation

Funder Name

Netherlands Cancer Institute (NKI) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration